T1	intervention 85 120	preoperative antibiotic prophylaxis
T2	condition 215 244	surgical site infection (SSI)
T3	eligibility 405 443	Women undergoing MRM for breast cancer
T4	intervention 826 847	intravenous cefazolin
T5	control 855 862	placebo
T6	outcome-Measure 1002 1036	SSI and other complications weekly
T7	No-of-participants 1061 1064	254
T8	duration 1041 1048	30 days
T9	outcome 1199 1223	overall incidence of SSI
T10	outcome 1281 1295	infection rate
T11	outcome 1582 1617	SI, incidence of hematoma or seroma
T12	control-value 1372 1376	15 %
T13	intervention-value 1380 1386	13.4 %
